Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Down 30% off the highs

<< Previous

Bullboard Posts

Next >>

Post by stocksarefunon Dec 14, 2021 3:13pm

196 Views

Post# 34230158

Down 30% off the highs

Anybody have insight into where this ends? We're assuming third party data news is the kicker here. But as the share price continues to slide, doesn't it imply that our ability to uplist becomes increasingly difficult?

CEO clearly wanted to send a signal to the market that everything is ok with that 2500 share purchase on Wednesday last week. Didn't work. Still in freefall.

Not nervous, but concerned, as I still doubt anyone here or their respective circles of friends/family haven't sold a share. Most that I know have actually bought more.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth